2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in Advanced Non-small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of...
2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical Studies in Advanced Colorectal Cancer
SAN FRANCISCO, and SUZHOU, China, June 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of...
ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical Studies on Immunotherapy-treated Advanced Malignant Melanoma
SAN FRANCISCO and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc (Suzhou) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of...
Eye Level Awards 2025: First-Ever Joint Ceremony for Hong Kong & Macau Students
Multiple international competitions inspired students to aim higher, winning praise from educators and parents alike. HONG KONG, May 27, 2025 /PRNewswire/ -- The annual Eye Level Awards Ceremony cum Carnival 2025, organized by Daekyo Hong Kong, was...
Aker Horizons ASA: First-quarter results 2025
FORNEBU, Norway, May 8, 2025 /PRNewswire/ -- Aker Horizons ASA (OSE: AKH), a developer of green energy and industry, today announced results for the first quarter 2025. Aker Horizons' net capital employed stood at NOK 4.3 billion, a decrease of NOK...
Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025
SAN FRANCISCO and SUZHOU, China, May 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...
"First-Ever Domination Powered by AIA" - MTR Kai Tak & Sung Wong Toi Station
Unleashing the First Themed Station: Total Domination, Engaging Every Customers! HONG KONG, April 10, 2025 /PRNewswire/ -- Bravo Media consistently offers premium advertising solutions to the market, providing unparalleled outdoor media assets for...
Seeking Investors: First-in-Class Immunotherapeutics for Cancer
ATLANTA, Jan. 27, 2025 /PRNewswire/ -- Cambium Oncology is pleased to share that their lead drug candidate, ANT308, recently demonstrated outstanding single-agent efficacy and safety in preclinical studies. The drug is mutation-agnostic, and the...
AXA and HK Express Launch New Flight Delay Parametric Protection
More Travel Protection Products for Better Flexibility Expanding into More Markets HONG KONG, Dec. 9, 2024 /PRNewswire/ -- AXA Hong Kong and Macau (AXA) and HK Express Airways (HK Express), with the support of AXA Partners, are pleased to announce...
